双歧杆菌三联活菌散联合水飞蓟宾胶囊治疗非酒精性脂肪性肝病患者的临床研究  

Clinical trial of bifid triple viable powder combined with silibinin capsules in the treatment of patients with non-alcoholic fatty liver disease

作　　者：江泳[1] 关玉龙[1] 韩小玲[2] 李群[3] 张旭[1] JIANG Yong;GUAN Yu-long;HAN Xiao-ling;LI Qun;ZHANG Xu(Department of Gastroenterology,The Third People’s Hospital of Bengbu,Bengbu 233000,Anhui Province,China;Department of Oncology,The Third People’s Hospital of Bengbu,Bengbu 233000,Anhui Province,China;Department of Endoscopy,The Third People’s Hospital of Bengbu,Bengbu 233000,Anhui Province,China)

机构地区：[1]蚌埠市第三人民医院消化内科,安徽蚌埠233000 [2]蚌埠市第三人民医院肿瘤内科,安徽蚌埠233000 [3]蚌埠市第三人民医院内镜室,安徽蚌埠233000

出　　处：《中国临床药理学杂志》2020年第15期2212-2215,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察双歧杆菌三联活菌散联合水飞蓟宾胶囊治疗非酒精性脂肪性肝病(NAFLD)患者的临床疗效。方法将我院治疗的NAFLD患者共92例随机分为试验组与对照组,各46例。对照组给予双歧杆菌三联活菌散,每次2 g,每天2次,口服;试验组在对照组的基础上给予水飞蓟宾胶囊,每次150 mg,每天3次,口服。2组均治疗6个月。观察2组患者肝功能、血脂、炎性因子、肝纤维化四项、总有效率及安全性的差别。结果治疗后,试验组和对照组的总有效率分别为91.31%和76.09%,差异有统计学意义(P<0.05)。治疗后,试验组和对照组谷丙转氨酶(GPT)分别为(35.76±7.21)和(41.98±8.54)U·L^-1,谷草转氨酶(GOT)分别为(39.61±14.64)和(49.34±16.25)U·L^-1,血清总胆固醇(TC)分别为(5.16±0.54)和(6.42±0.73)mmol·L^-1,三酰甘油(TG)分别为(1.71±0.73)和(2.13±0.45)mmol·L^-1,血清白细胞介素-6(IL-6)水平分别为(13.52±2.24)和(18.35±2.57)μg·L^-1,肿瘤坏死因子-α(TNF-α)分别为(21.63±5.14)和(31.27±7.63)μg·L^-1,差异均有统计意义(均P<0.05)。治疗后,2组透明质酸酶(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PCⅢ)和Ⅳ型胶原(PCⅣ)水平均较治疗前降低,且试验组低于对照组(均P<0.05)。治疗后2组药物不良反应发生率均为2.17%,差异无统计学意义(P>0.05)。结论双歧杆菌三联活菌散联合水飞蓟宾胶囊治疗法能显著提高肝功能,降低血脂,减少炎性因子以及改善肝纤维化情况,对NAFLD的治疗效果较好。Objective To observe the clinical efficacy of bifid triple viable powder combined with silibinin capsules in the treatment of patients with non-alcoholic fatty liver disease(NAFLD).Methods A total of 92 patients with NAFLD who were treated in our hospital were randomly divided into treatment group and control group,with 46 cases in each group.Control group was treated with bifid triple viable powder 2 g,bid,treatment group was treated with silibinin capsules 150 mg,tid,on the basis of control group.Both groups were treated for 6 months.The levels of liver function,blood lipid,inflammatory factors,four items of liver fibrosis,total effective rates and safety between the two groups were observed.Results After treatment,the total effective rates of treatment group and control group were 91.31% and 76.09%,with significant difference(P<0.05).The glutamic pyruvic transaminase(GPT)of treatment group and control group were(35.76±7.21)and(41.98±8.54)U·L^-1,the glutamic oxaloacetic transaminase(GOT)were(39.61±14.64)and(49.34±16.25)U·L^-1,the total cholesterol(TC)were(5.16±0.54)and(6.42±0.73)mmol·L^-1,the triglyceride(TG)were(1.71±0.73)and(2.13±0.45)mmol·L^-1,the serum interleukin-6(IL-6)levels were(13.52±2.24)and(18.35±2.57)μg·L^-1,the tumor necrosis factor-α(TNF-α)were(21.63±5.14)and(31.27±7.63)μg·L-1,all with significant difference(all P<0.05).After treatment,the levels of hyaluronidase(HA),laminin(LN),procollagen Ⅲ(PC Ⅲ)and collagen Ⅳ(PC Ⅳ)in two groups were all decreased,and treatment group were lower than control group(all P<0.05).After treatment,the incidence of adverse drug reactions in both groups was 2.17%,without significant difference(P>0.05).Conclusion The therapy of bifid triple viable powder combined with silibinin capsules treatment can improve the liver function,reduce the level of blood lipid,alleviate inflammatory factors and improve the situation of liver fibrosis,which has a positive effect in patients with NAFLD.

关 键 词：水飞蓟宾胶囊 双歧杆菌三联活菌散 非酒精性脂肪性肝病 肝功能 肝纤维化 

分 类 号：R97[医药卫生—药品]